The case for combining treatments for primary sclerosing cholangitis.

[1]  R. Elferink,et al.  Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis , 2018, Scientific Reports.

[2]  N. LaRusso,et al.  PC.01.8 THE AESOP TRIAL: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS , 2018 .

[3]  M. Trauner,et al.  New therapeutic concepts in bile acid transport and signaling for management of cholestasis , 2017, Hepatology.

[4]  David E. J. Jones,et al.  Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study , 2017, The Lancet.

[5]  David E. J. Jones,et al.  Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis , 2017, Digestive Diseases.

[6]  J. Reguła,et al.  A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. , 2016, The New England journal of medicine.

[7]  J. Polli,et al.  Slc10a2-null mice uncover colon cancer-promoting actions of endogenous fecal bile acids. , 2015, Carcinogenesis.

[8]  M. Trauner,et al.  New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. , 2015, Journal of hepatology.

[9]  G. Frantz,et al.  A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. , 2002, The American journal of pathology.